Nine Denosumab Biosimilars and Counting. The Real Competition Is in the Provider Channel.

The denosumab biosimilar market has gone from quiet anticipation to a full sprint. In the past twelve months, the FDA has approved nine pairs of biosimilars referencing Prolia and Xgeva. Six have already launched commercially, with more expected throughout 2026. The latest, Teva’s Ponlimsi, was approved on March 30.

For a biologic franchise with combined U.S. sales exceeding $5 billion annually, this level of competition was expected. But the speed and volume of market entry raise questions that go well beyond the approval headlines.

Both Prolia and Xgeva are physician-administered products. Prolia is given as a subcutaneous injection every six months in a provider’s office for osteoporosis. Xgeva is used in oncology settings for skeletal-related events. Both are reimbursed under the medical benefit, which means the competitive dynamics here look nothing like what plays out on a pharmacy formulary.

In the medical benefit channel, uptake is shaped by how providers acquire and get reimbursed for drugs. Physicians buy the product, administer it, and bill the payer at a rate tied to the Average Sales Price. The margin between what a practice pays for a biosimilar and what it collects from the payer is what makes a product financially viable in a clinic setting. A biosimilar priced lower than the reference product only wins if the reimbursement math works for the provider who has to stock it, store it, and manage the billing.

That reimbursement math is still evolving. ASP-based rates for newly launched biosimilars can shift meaningfully in their first few quarters on the market as CMS recalculates based on actual sales data. Providers watching those fluctuations may hesitate to commit to a particular biosimilar early on, especially when nine options are entering at roughly the same time. The result could be a slower uptake curve than the number of approved products would suggest.

For health plans, the lever is different than it would be on the pharmacy side. There are no formulary tiers to manage. Instead, plans can influence adoption through medical policy updates, provider incentive structures, and reimbursement rate design. Some plans may adjust payment rates to encourage biosimilar use. Others may implement prior authorization or site-of-care requirements that steer toward lower-cost alternatives.

Key Takeaway
The denosumab biosimilar wave is the clearest test yet of whether concentrated competition in a high-value medical benefit category can translate into real savings, or whether the buy-and-bill economics and reimbursement complexity of the provider channel will slow the price erosion that competition is supposed to deliver.